Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)

SHE:301281 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	156.62	178.13	325.22	148.97	66.01	37.44
Short-Term Investments	-	-	210.26	-	-	-
Trading Asset Securities	241.04	254.43	150.54	-	-	-
Cash & Short-Term Investments	397.65	432.56	686.02	148.97	66.01	37.44
Cash Growth	-33.61%	-36.95%	360.50%	125.69%	76.29%	10.48%
Accounts Receivable	90.7	95.85	75.85	56.87	43.71	66.39
Other Receivables	26.85	27.11	0.65	0.31	0.69	0.54
Receivables	117.55	122.96	76.5	57.18	44.4	66.93
Inventory	142.45	128.94	108.05	67.92	86.44	70.95
Other Current Assets	22.52	6.26	8.22	8.2	6.53	1.37
Total Current Assets	680.17	690.73	878.79	282.27	203.38	176.7
Property, Plant & Equipment	505.98	477	314.2	308.83	290.27	217.61
Long-Term Investments	190.48	190.31	184.08	-	-	-
Goodwill	1.82	1.82	-	-	-	-
Other Intangible Assets	105.63	107.17	46.02	49.08	51.76	54.76
Long-Term Deferred Tax Assets	3.11	3.06	2.92	2.09	1.62	1.69
Long-Term Deferred Charges	2.32	2.39	0.73	1.73	3.15	4.45
Other Long-Term Assets	86.52	79.98	43.22	7.79	9.34	3.33
Total Assets	1,576	1,552	1,470	651.79	559.51	458.53
Accounts Payable	36.56	42.25	50.18	54.98	60.58	28.89
Accrued Expenses	11.57	44.59	39.71	29.23	23.65	24.9
Short-Term Debt	3.48	-	-	-	-	-
Current Income Taxes Payable	3.45	1.08	0	-	4.59	7.98
Current Unearned Revenue	5.12	20.24	3.5	3.02	3.09	12.75
Other Current Liabilities	42.54	11.63	17.75	20.64	18.83	25.26
Total Current Liabilities	102.71	119.78	111.14	107.86	110.75	99.79
Long-Term Debt	63.19	45.66	-	-	-	-
Long-Term Unearned Revenue	9.02	9.27	10.53	9.04	10.11	10.39
Long-Term Deferred Tax Liabilities	17.46	17.78	17.25	15.16	7.66	6.72
Other Long-Term Liabilities	0.38	0.38	-	-	-	-
Total Liabilities	192.77	192.87	138.93	132.06	128.52	116.9
Common Stock	108.29	108.29	108.29	58	58	58
Additional Paid-In Capital	907.67	907.67	909.97	195.34	195.34	186.45
Retained Earnings	363.35	340.26	312.3	266.2	174.93	96.75
Comprehensive Income & Other	3.14	2.57	0.48	0.19	2.72	0.43
Total Common Equity	1,382	1,359	1,331	519.73	430.98	341.63
Minority Interest	0.79	0.81	-	-	-	-
Shareholders' Equity	1,383	1,360	1,331	519.73	430.98	341.63
Total Liabilities & Equity	1,576	1,552	1,470	651.79	559.51	458.53
Total Debt	66.67	45.66	-	-	-	-
Net Cash (Debt)	330.99	386.9	686.02	148.97	66.01	37.44
Net Cash Growth	-44.74%	-43.60%	360.50%	125.69%	76.29%	-
Net Cash Per Share	3.08	3.59	6.77	1.83	0.81	0.46
Filing Date Shares Outstanding	108.29	108.29	108.29	81.2	81.2	81.2
Total Common Shares Outstanding	108.29	108.29	108.29	81.2	81.2	81.2
Working Capital	577.45	570.95	767.65	174.4	92.64	76.91
Book Value Per Share	12.77	12.55	12.29	6.40	5.31	4.21
Tangible Book Value	1,275	1,250	1,285	470.65	379.23	286.88
Tangible Book Value Per Share	11.77	11.54	11.87	5.80	4.67	3.53
Buildings	-	216.15	213.26	208.05	186.34	152.37
Machinery	-	342.54	316.21	275.82	210.37	193.11
Construction In Progress	-	183.15	12.15	19.99	66.23	22.28

Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.